Top marks for Cherwell’s Redipor prepared microbial media products
Extensive range of ready-to-use culture media available in bottles and plates.
A recent customer satisfaction survey has affirmed that the vast majority would recommend Cherwell and its Redipor microbiological media products to a colleague. Value for money, excellent customer service and product quality were all key factors contributing to the very positive outcome of this survey. These results are evidenced by Redipor’s growing user base within the pharmaceutical and associated industries both domestically and across Europe. Therefore, to accommodate all customers, Cherwell has just released both UK and Euro versions of its 2018/19 Redipor Prepared Media price list, now available to download from Cherwell’s website.
Redipor prepared media products scored highly with customers in Cherwell’s recent survey to achieve an impressive Net Promoter Score of +76 (from a range of -100 to +100). Customer comments as to ‘Why Cherwell?’ included: ”The excellent service; great pricing; exceeding expectations with delivery times; helping us out in a crisis; flexibility by preparing bespoke media; pragmatic advice; and realistic timeframes. What more could anyone want?”
Meeting varying customer needs, such as for environmental monitoring, sterility testing and validation applications, the new Redipor price list details the extensive range of ready-to-use culture media available in bottles and plates. Cherwell provides a selection of the most commonly requested types, many of which are available from stock for next day delivery. In addition to those included in the price list, Cherwell offers many other bespoke products which are made to order with short lead times and small minimum order requirements. Discounts are available for high volume and standing orders.
“With customer satisfaction and ease of access in mind, we have laid out our new Redipor price list to enable straightforward reference of ordering information and products,” said Andrew Ramage, Cherwell’s Microbiology Product Specialist. “And if customers can't find exactly what they need, we’d like to hear from them as we frequently adapt to meet specific requirements, be it the media formulation, format, packaging or quantity. We are also very happy to provide rapid quotations and flexible delivery schedules.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...